(VIANEWS) – NEOEN (NEOEN.PA), SPBK 1 NORDMØRE (SNOR.OL), SPBK1 RINGERIKE (RING.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. NEOEN (NEOEN.PA)
48.5% sales growth and 7.39% return on equity
Neoen S.A., an independent renewable energy production company, engages in the development and operation of renewable energy power plants. The company operates through Solar Power, Wind Power, Storage, Farm-Down, Development and Investments, and Eliminations segments. It operates in Argentina, Australia, Canada, Ecuador, the United States, Finland, France, Ireland, Italy, Jamaica, Mexico, Mozambique, Portugal, El Salvador, Sweden, and Zambia. Neoen S.A. was incorporated in 2008 and is headquartered in Paris, France. Neoen S.A. operates as a subsidiary of Impala SAS.
Earnings Per Share
As for profitability, NEOEN has a trailing twelve months EPS of €1.14.
PE Ratio
NEOEN has a trailing twelve months price to earnings ratio of 24.32. Meaning, the purchaser of the share is investing €24.32 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.39%.
Sales Growth
NEOEN’s sales growth is 63.4% for the ongoing quarter and 48.5% for the next.
Volume
Today’s last reported volume for NEOEN is 10678 which is 90.72% below its average volume of 115186.
Yearly Top and Bottom Value
NEOEN’s stock is valued at €27.72 at 07:20 EST, way under its 52-week high of €42.80 and higher than its 52-week low of €25.72.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on May 17, 2023, the estimated forward annual dividend rate is 0.12 and the estimated forward annual dividend yield is 0.45%.
More news about NEOEN.
2. SPBK 1 NORDMØRE (SNOR.OL)
25.4% sales growth and 8.68% return on equity
SpareBank 1 Nordmøre provides various banking services in Norway. The company provides business insurance products, which include liability, work machine, condominium, car, bus, boat, cyber, crime, truck, property, commercial building, project, trailer, and transport insurance; personal insurance products, such as life, business, travel, and accidental insurance products; pension products; bank cards; payment and debt collection services; and mobile and online banking services. It also offers bank guarantees, operating credit products for agriculture, and factoring and leasing products and services, as well as savings and deposit accounts, refinancing, and mortgage services. The company was founded in 1835 and is based in Kristiansund, Norway. SpareBank 1 Nordmøre is a subsidiary of SpareBank 1 Gruppen AS.
Earnings Per Share
As for profitability, SPBK 1 NORDMØRE has a trailing twelve months EPS of kr12.41.
PE Ratio
SPBK 1 NORDMØRE has a trailing twelve months price to earnings ratio of 9.75. Meaning, the purchaser of the share is investing kr9.75 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.68%.
More news about SPBK 1 NORDMØRE.
3. SPBK1 RINGERIKE (RING.OL)
21.7% sales growth and 10.56% return on equity
SpareBank 1 Ringerike Hadeland provides various banking products and services to private and corporate customers in Norway. The company offers saving, current, deposit, and currency accounts; vehicle, house and travel, and animal insurance products, as well as life, child, disability, critical illness, accident, health, and business and personal insurance products; mobile and online banking services; and debit and credit cards. It also provides mortgages; car, boat, and other vehicles; consumer and other loans; and bank guarantees, corporate and construction loans, liquidity loans with a government guarantee, and operating credit for agriculture, as well as factoring, leasing, and overdraft services. In addition, the company offers services for buying and selling property; accounting services; pension products; and savings and investment products. The company was founded in 1833 and is based in Hønefoss, Norway.
Earnings Per Share
As for profitability, SPBK1 RINGERIKE has a trailing twelve months EPS of kr27.12.
PE Ratio
SPBK1 RINGERIKE has a trailing twelve months price to earnings ratio of 11.28. Meaning, the purchaser of the share is investing kr11.28 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.56%.
More news about SPBK1 RINGERIKE.
4. VERALLIA (VRLA.PA)
19.7% sales growth and 44.03% return on equity
Verallia Société Anonyme produces and sells glass packaging products for beverages and food industry worldwide. It also provides bottles for still and sparkling wines, spirits, beers, soft drinks, and oils. The company offers jars for baby food, dairy products, jams, honey, spreads, condiments, sauces, and preserves. Verallia Société Anonyme was founded in 1827 and is based in Courbevoie, France.
Earnings Per Share
As for profitability, VERALLIA has a trailing twelve months EPS of €4.08.
PE Ratio
VERALLIA has a trailing twelve months price to earnings ratio of 10.29. Meaning, the purchaser of the share is investing €10.29 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 44.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.7%, now sitting on 3.86B for the twelve trailing months.
More news about VERALLIA.
5. NAVAMEDIC (NAVA.OL)
17.3% sales growth and 10.19% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.18.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 27.12. Meaning, the purchaser of the share is investing kr27.12 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.19%.
Moving Average
NAVAMEDIC’s worth is way below its 50-day moving average of kr36.01 and way below its 200-day moving average of kr36.31.
Yearly Top and Bottom Value
NAVAMEDIC’s stock is valued at kr32.00 at 07:20 EST, way below its 52-week high of kr43.60 and higher than its 52-week low of kr29.20.
Sales Growth
NAVAMEDIC’s sales growth is 22.8% for the ongoing quarter and 17.3% for the next.
Volume
Today’s last reported volume for NAVAMEDIC is 33521 which is 1.13% above its average volume of 33145.
More news about NAVAMEDIC.
6. BAKKAFROST (BAKKA.OL)
11.7% sales growth and 13.83% return on equity
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products under the Bakkafrost and Havsbrún brands in North America, Western Europe, Eastern Europe, Asia, and internationally. It operates through four segments: Farming FO; Farming SCT; Value Added Products; and Fishmeal, Oil and Fish Feed. The company is involved in the breeding and on-growing of salmon; harvesting, sale, and distribution of salmon; salmon farming, harvest, filleting, sales, and administration; and production of skinless and boneless portions of salmon. It also produces and sells fishmeal, fish oil, and fish feed. In addition, it engages in production of styrofoam boxes, and biogas and fertilizer; and operates trading of fishes, lumpfish farming business, and freight transportation of goods, as well as produce and sell canned fish products. P/F Bakkafrost was founded in 1968 and is headquartered in Glyvrar, Denmark.
Earnings Per Share
As for profitability, BAKKAFROST has a trailing twelve months EPS of kr11.5.
PE Ratio
BAKKAFROST has a trailing twelve months price to earnings ratio of 46.04. Meaning, the purchaser of the share is investing kr46.04 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.83%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 25%, now sitting on 7.54B for the twelve trailing months.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is a negative 8.9% and positive 68.9% for the next.
Volume
Today’s last reported volume for BAKKAFROST is 19112 which is 74.19% below its average volume of 74060.
More news about BAKKAFROST.
